论文部分内容阅读
目的探讨给予慢性丙型肝炎(CHC)患者长效与短效α-干扰素联合利巴韦林治疗的效果。方法 110例CHC患者作为研究对象,将其随机分为长效组与短效组,各55例。短效组给予重组干扰素α-2b联合利巴韦林治疗,长效组给予聚乙二醇干扰素α-2a联合利巴韦林治疗,对比分析两组肝功能改善情况、免疫应答率及不良反应。结果治疗后第2年短效组的天门冬氨酸转氨酶(AST)恢复正常率为72.7%、丙氨酸转氨酶(ALT)恢复正常率为72.7%、谷氨酰转肽酶(GGT)恢复正常率为70.9%、远期有效率为69.1%,均明显低于长效组的89.1%、89.1%、87.3%、85.5%,差异具有统计学意义(P<0.05);短效组的复发率为29.1%,明显高于长效组的12.7%,差异具有统计学意义(P<0.05)。治疗后第2年,短效组的持续应答率为72.7%,明显低于长效组的89.1%,差异具有统计学意义(P<0.05)。长效组不良反应发生率为7.3%,明显低于短效组的21.8%,差异具有统计学意义(P<0.05)。结论给予CHC患者长效干扰素联合利巴韦林治疗效果显著,可明显改善肝功能,减少不良反应发生,提高生存质量,且应用安全性高,值得在临床上广泛应用。
Objective To investigate the effect of long-acting and short-acting α-interferon combined with ribavirin in patients with chronic hepatitis C (CHC). Methods A total of 110 patients with CHC were enrolled in this study. They were randomly divided into long-acting group and short-acting group, 55 cases each. The short-acting group was treated with recombinant interferon α-2b and ribavirin, and the long-acting group was treated with pegylated interferon α-2a and ribavirin. The improvement of liver function and immune response rate were compared between the two groups Adverse reactions. Results The recovery of aspartate aminotransferase (AST) was 72.7%, the recovery of alanine aminotransferase (ALT) was 72.7% and the activity of glutamyl transpeptidase (GGT) returned to normal in the second year after treatment The rate of long-term effective rate was 69.1%, which was significantly lower than 89.1%, 89.1%, 87.3% and 85.5% of the long-acting group, the difference was statistically significant (P <0.05) (29.1%), which was significantly higher than that of the long-acting group (12.7%). The difference was statistically significant (P <0.05). In the second year after treatment, the sustained response rate of the short-term group was 72.7%, which was significantly lower than that of the long-term group (89.1%). The difference was statistically significant (P <0.05). The incidence of adverse reactions in the long-acting group was 7.3%, which was significantly lower than that in the short-acting group (21.8%), the difference was statistically significant (P <0.05). Conclusion Long-acting interferon and ribavirin are effective in CHC patients, which can significantly improve liver function, reduce adverse reactions, improve quality of life, and have high safety. It is worth widely used in clinical practice.